

# Turkmenistan

## Tuberculosis profile

Population 2016

5.7 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.43 (0.38–0.48)	7.6 (6.7–8.5)
Mortality (HIV+TB only)	0.037 (0.016–0.066)	0.65 (0.28–1.2)
Incidence (includes HIV+TB)	3.4 (2.6–4.3)	60 (46–76)
Incidence (HIV+TB only)	0.18 (0.084–0.31)	3.2 (1.5–5.5)
Incidence (MDR/RR-TB)**	0.83 (0.65–1)	15 (11–18)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.19 (0.14–0.24)	0.98 (0.73–1.2)	1.2 (0.88–1.5)
Males	0.2 (0.15–0.25)	2 (1.5–2.6)	2.2 (1.7–2.8)
Total	0.39 (0.29–0.49)	3 (2.3–3.8)	3.4 (2.6–4.3)

TB case notifications, 2016

Total cases notified	2 340
Total new and relapse	2 068
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	78%
- % bacteriologically confirmed among pulmonary	56%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	61% (48–79)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.14 (0.1–0.18)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy	0	

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			360 (300–420)
Estimated % of TB cases with MDR/RR-TB	14% (11–17)	38% (28–49)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 560, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 569, XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2015	87%	1 669
Previously treated cases registered in 2015	81%	211
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014	67%	213
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	1.8
Funding source: domestic, 100% international, 0% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

